NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6.62 mln
Float4.15 mln
Earnings Date08/17/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
12
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-172
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Acurx Pharmaceuticals is a New York-based drug development company focused on creating new antibiotics to fight serious bacterial infections. Its furthest-along drug, ibezapolstat, works differently from existing antibiotics by blocking a specific bacterial enzyme, and is currently being tested in mid-stage clinical trials for a dangerous gut infection called C. difficile. The company is also working on a second treatment, ACX-375C, designed to combat several hard-to-treat bacteria, including MRSA and other strains that have developed resistance to common antibiotics.
